This provider's $11.7M in total Medicare payments ranks in the 99th percentile of Nuclear Medicine providers nationally.
Medicare payments to this provider grew 485% from 2016 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 233% in 2017
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2016 | $445.13 | $152.44 | 2.92x | $292.69 | $324.8K | 1.6K | 1.6K |
| 2017 | $737.09 | $269.60 | 2.73x | $467.49 | $1.1M | 4.0K | 4.0K |
| 2018 | $919.93 | $333.44 | 2.76x | $586.49 | $1.7M | 5.0K | 4.9K |
| 2019 | $865.81 | $330.80 | 2.62x | $535.01 | $1.8M | 5.5K | 5.4K |
| 2020 | $831.91 | $260.15 | 3.20x | $571.76 | $1.8M | 5.5K | 5.3K |
| 2021 | $784.26 | $233.16 | 3.36x | $551.10 | $2.0M | 5.7K | 5.4K |
| 2022 | $591.07 | $204.65 | 2.89x | $386.42 | $1.2M | 4.2K | 4.1K |
| 2023 | $1.4K | $379.48 | 3.60x | $985.67 | $1.9M | 5.7K | 4.4K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 78815 | Nuclear medicine study with CT imaging skull base to mid-thigh | 6.4K | $5.0M | $781.48 | 3.43x |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 4.0K | $1.6M | $398.14 | 1.80x |
| A9584 | Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | 547 | $1.2M | $2.1K | 1.72x |
| 78816 | Nuclear medicine study with CT imaging whole body | 821 | $647.5K | $788.63 | 3.41x |
| 78306 | Bone and/or joint imaging, whole body | 2.0K | $420.1K | $209.76 | 2.53x |
| 74177 | CT scan of abdomen and pelvis with contrast | 1.6K | $344.0K | $220.23 | 3.99x |
| A9570 | Indium in-111 labeled autologous white blood cells, diagnostic, per study dose | 152 | $244.4K | $1.6K | 2.27x |
| 71260 | CT scan chest with contrast | 2.3K | $215.7K | $92.70 | 6.54x |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | 422 | $164.6K | $390.06 | 1.98x |
| A9588 | Fluciclovine f-18, diagnostic, 1 millicurie | 388 | $159.0K | $409.91 | 2.28x |
| 78803 | Nuclear medicine study of radioactive material distribution | 494 | $131.6K | $266.36 | 2.59x |
| 78315 | Bone and/or joint imaging, 3 phase study | 454 | $117.4K | $258.56 | 2.34x |
| A9520 | Technetium tc-99m tilmanocept, diagnostic, up to 0.5 millicuries | 56 | $113.9K | $2.0K | 1.53x |
| 71250 | CT scan chest | 1.3K | $104.8K | $80.79 | 7.28x |
| 78264 | Stomach emptying study | 427 | $101.3K | $237.21 | 1.84x |
| A9562 | Technetium tc-99m mertiatide, diagnostic, per study dose, up to 15 millicuries | 182 | $81.5K | $447.71 | 1.77x |
| 75574 | CT scan of heart blood vessels and grafts with contrast dye | 315 | $80.5K | $255.56 | 4.18x |
| 78607 | Nuclear medicine study of brain | 236 | $69.2K | $293.28 | 2.64x |
| 74178 | CT scan of abdomen and pelvis before and after contrast | 277 | $68.4K | $246.96 | 6.38x |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 711 | $66.4K | $93.40 | 1.88x |
This provider submits charges 3.01 times higher than what Medicare actually pays.
A markup ratio of 3.01x means for every $100 Medicare pays, this provider initially charges $301. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data